MAOB and Parkinson disease: However, while MAO-B inhibitors selegiline (L-deprenyl) and rasagiline are approved for the symptomatic treatment of PD, clinical trials with MAO-B inhibitors have shown no clear benefit to slow down AD-related cognitive decline [6, 33].